half-life is 168 hours. that is why your injection day barely matters.
The title is the argument: half-life is 168 hours. that is why your injection day barely matters. Here is the rest of it.
Numbers, in the order they matter: 168 hours.
Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.
The half-life explanation was the thing that made weekly dosing intuitive for me rather than arbitrary.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
The mental model, in four steps, that makes the rest of this site legible.
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.
[deleted]
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
This. Albumin binding and modification are why the half-life is what it is, and it is a design decision rather than an accident.
Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
What was the exposure in that experiment relative to therapeutic?
Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.
Which receptor arm are you attributing that to?
a mechanism you can state is not a mechanism you have demonstrated
receptor distribution is why the side effects are where they are
incretin effect first, then everything else in this board makes sense
- 1The mental model, in four steps, that makes the rest of this site legible.…10 comments in this branch · started by u/trialwatch_theo
- 2GIP receptor biology is genuinely unsettled — there is a live argument about…6 comments in this branch · started by u/nora_lundgren